<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146663</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-105</org_study_id>
    <secondary_id>2016-003287-39</secondary_id>
    <nct_id>NCT03146663</nct_id>
  </id_info>
  <brief_title>NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer</brief_title>
  <official_title>A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuCana plc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuCana plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2)
      in patients with ovarian cancer. The primary objective is to determine the anti-tumor
      activity of NUC-1031 at the selected dose level (500 mg/m2 or 750 mg/m2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 20 patients will be treated at each dose in Part I of the study. In Part II of the
      study, one of the treatment dose levels will be selected for further evaluation. The dose
      selection will be based on clinical and laboratory assessments of patients recruited in Part
      I. Patients will only participate in either Part I or II. A total of 64 patients will be
      treated in Part I and Part II combined.

      Eligible consenting patients will receive NUC-1031 by IV infusion on days 1, 8 and 15 of each
      28-day cycle. Patients will continue to receive NUC-1031 until the occurrence of disease
      progression. Patients will undergo imaging every 8 weeks. After disease progression, patients
      will be followed for overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed at approximately 24 weeks following the last patient enrolled</time_frame>
    <description>ORR is defined as the number of patients achieving a confirmed response (CR or PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in tumor size</measure>
    <time_frame>Assessed every 8 weeks for up to 36 months</time_frame>
    <description>The percentage change in the total measurement of target lesions from the pre-treatment scan to the total measurement of target lesions at each scheduled scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (per RECIST)</measure>
    <time_frame>Assessed every 8 weeks for up to 36 months</time_frame>
    <description>Progression-free survival will be calculated from the start of treatment to the date of progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Assessed every 12 weeks following disease progression for up to 36 months</time_frame>
    <description>Overall survival will be calculated from the start of treatment to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (per NCI CTCAE v4), changes in vitals signs and laboratory parameters</measure>
    <time_frame>Assessed from the time of consent until 30 days following the last NUC-1031 dose administration</time_frame>
    <description>Evaluation of safety and tolerability of NUC-1031</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>NUC-1031 500 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NUC-1031 500 mg/m2 on days 1, 8, and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NUC-1031 750 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NUC-1031 750 mg/m2 on Days 1, 8, and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NUC-1031 500 mg</intervention_name>
    <description>NUC-1031 500 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.</description>
    <arm_group_label>NUC-1031 500 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NUC-1031 750mg</intervention_name>
    <description>NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle</description>
    <arm_group_label>NUC-1031 750 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed written informed consent.

          2. Original diagnosis and/or histological confirmation of high-grade serous, high-grade
             endometrioid, undifferentiated/unclassifiable epithelial ovarian, fallopian tube or
             primary peritoneal cancer.

          3. Time from the last line of platinum-based chemotherapy of less than 6 months.

          4. Received at least 3 prior chemotherapy-containing regimens.

          5. Age â‰¥18 years.

          6. Ability to comply with protocol requirements.

          7. Patients are not of childbearing potential or they must agree to use a physical method
             of contraception.

        Exclusion Criteria:

          1. Disease that progressed while receiving initial line of platinum-based chemotherapy.

          2. Received fewer than 3 prior chemotherapy-containing regimens.

          3. Prior therapy with single-agent gemcitabine.

          4. Prior history of hypersensitivity to gemcitabine.

          5. Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone
             pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within 21 days
             of first receipt of study drug. Hormone therapy within 14 days of first receipt of
             study drug.

          6. Residual side effects from chemotherapy or radiation, which have not gotten better
             except for nerve pain or tingling or hair loss.

          7. Patients who have a history of another type of cancer diagnosed within the past 5
             years, with the exception of adequately treated non-melanoma skin cancer curatively
             treated cervical cancer or ductal carcinoma in situ (DCIS) of the breast.

          8. Presence of an serious illness, uncontrolled illness, or active infection requiring IV
             antibiotics.

          9. Presence of any serious illnesses, serious medical conditions, serious medical
             history, active bacterial or viral infections including hepatitis B or C, or known to
             be HIV positive.

         10. Currently pregnant, lactating or breastfeeding.

         11. History of blocked intestines because of ovarian cancer, unless fully resolved.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher B Wood, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>NuCana plc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Coy</last_name>
    <phone>+44 7397009645</phone>
    <email>Ruth.Coy@chiltern.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heather Dalton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joseph Buscema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>prumney@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Krishnansu Tewari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ling Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Affiliates - Ocala</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Samuel E Myrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>rmccrery@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Gail Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - Florida</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Spitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>clandini@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Moroney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435-2150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica A Thomes-Pepin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - HCA Health Midwest</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristopher LyBarger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nashville Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Brittany.Goodloe@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - South Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael G Teneriello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark J Messing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - Ft Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prasnthi Ganesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Ave</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Noelle G Cloven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Donald A Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institue</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>Erik.Bailey@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Press, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Research UK Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>moira.stewart1@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Charley M Gourley, MB ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Clinical Trial Unit</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Rai</last_name>
    </contact>
    <contact_backup>
      <email>Debbie.Rai@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Roxburgh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICR Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Kylie.Fitch@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Susana Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Emily.Pickford@imperial.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jonathan Krell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>a.summers@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rowan Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Didem.Agdiran@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michelle Lockley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trialadministrator02@oncology.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Shibani Nicum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-resistant</keyword>
  <keyword>ovarian neoplasm</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>ovarian diseases</keyword>
  <keyword>cancer of the ovary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

